The development of positive inotropic agents for chronic heart failure: how have we gone astray?

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Journal of the American College of Cardiology

• Publication date

  1993-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0735-1097(93)90474-FPMID 8397231
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure

  2005cited by this paper
• Quabain: Temporal relationship between the inotropic effect and the in vitro binding to, and dissociation from, (Na++K+)-activated ATPase

  2004cited by this paper
• Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study.

  1993cited by this paper
• Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors.

  1993cited by this paper
• The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.

  1992cited by this paper
• Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.

  1992cited by this paper
• A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.

  1992cited by this paper
• Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial.

  1992cited by this paper
• Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy.

  1991cited by this paper
• Randomized Study to Evaluate the Relation Between Oral Isosorbide Dinitrate Dosing Interval and the Development of Early Tolerance to Its Effect on Left Ventricular Filling Pressure in Patients With Chronic Heart Failure

  1991cited by this paper
• Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.

  1991cited by this paper
• Xamoterol in severe heart failure.

  1990cited by this paper
• Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group.

  1990cited by this paper
• Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings.

  1989cited by this paper
• A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.

  1989cited by this paper
• Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction.

  1988cited by this paper
• Long-term effects of xamoterol on left ventricular diastolic function and late remodeling: a study in patients with anterior myocardial infarction and single-vessel disease.

  1988cited by this paper
• DOUBLE-BLIND PLACEBO-CONTROLLED COMPARISON OF DIGOXIN AND XAMOTEROL IN CHRONIC HEART FAILURE

  1988cited by this paper
• A controlled trial of digoxin in congestive heart failure.

  1988cited by this paper
• Cumulative Hemodynamic Response to Short‐Term Treatment with Flosequinan (BTS 49465), a New Direct‐Acting Vasodilator Drug, in Severe Chronic Congestive Heart Failure

  1988cited by this paper
• Should digoxin be the drug of first choice after diuretics in chronic congestive heart failure?

  1988cited by this paper
• Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group.

  1988cited by this paper
• Cyclic AMP-dependent and cyclic AMP-independent actions of a novel cardiotonic agent, OPC-8212

  1988cited by this paper
• Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure.

  1988cited by this paper
• OPC-8212 in the treatment of congestive heart failure: Results of a pilot study

  1988cited by this paper
• Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study

  1987cited by this paper
• Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure.

  1987cited by this paper
• Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure.

  1987cited by this paper
• Survival in congestive heart failure during treatment with drugs with positive inotropic actions.

  1987cited by this paper
• Baroreceptor function in congestive heart failure: effect on neurohumoral activation and regional vascular resistance.

  1987cited by this paper
• Subclasses of Cyclic AMP‐Specific Phosphodiesterase in Left Ventricular Muscle and Their Involvement in Regulating Myocardial Contractility

  1987cited by this paper
• Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure

  1986cited by this paper
• Identification of the direct vasodilator effect of milrinone with an isolated limb preparation in patients with chronic congestive heart failure.

  1986cited by this paper
• Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.

  1986cited by this paper
• MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response.

  1985cited by this paper
• Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.

  1985cited by this paper
• Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation.

  1985cited by this paper
• Selective regulation of beta-1 and beta-2 adrenergic receptors by atypical agonists.

  1985cited by this paper
• Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement.

  1985cited by this paper
• Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure.

  1984cited by this paper
• Hydralazine therapy in chronic congestive heart failure. Sustained central and regional hemodynamic responses.

  1984cited by this paper
• Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone.

  1984cited by this paper
• Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine.

  1984cited by this paper
• Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol.

  1984cited by this paper
• Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure.

  1984cited by this paper
• Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure.

  1984cited by this paper
• Side effects of amrinone therapy.

  1983cited by this paper
• Regression of myocardial cellular hypertrophy with vasodilator therapy in chronic congestive heart failure associated with idiopathic dilated cardiomyopathy.

  1983cited by this paper
• Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure.

  1983cited by this paper
• Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure.

  1983cited by this paper
• Pirbuterol, An Oral Beta‐adrenergic Receptor Agonist, in the Treatment of Chronic Cardiac Failure

  1982cited by this paper
• Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure.

  1982cited by this paper
• Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

  1982cited by this paper
• Heart failure in outpatients: a randomized trial of digoxin versus placebo.

  1982cited by this paper
• Hemodynamic Effects of Oral Pirbuterol in Chronic Severe Congestive Heart Failure

  1981cited by this paper
• Hemodynamic actions of prenalterol in severe congestive heart failure due to chronic coronary disease.

  1981cited by this paper
• Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.

  1981cited by this paper
• Long-term benefit of dobutamine in patients with congestive cardiomyopathy.

  1980cited by this paper
• Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure.

  1980cited by this paper
• Cyclic AMP and the pathogenesis of myocardial injury.

  1980cited by this paper
• Dose requirements of hydralazine in patients with severe chronic congestive heart failure.

  1980cited by this paper
• The role of cyclic adenosine monophosphate in adrenergic effects on ventricular vulnerability to fibrillation in the isolated perfused rat heart.

  1978cited by this paper
• Hemodynamic assessment of amrinone. A new inotropic agent.

  1978cited by this paper
• Beneficial Effect of Salbutamol on Cardiac Function in Severe Congestive Cardiomyopathy: Effect on Systolic and Diastolic Function of the Left Ventricle

  1978cited by this paper
• Direct and reflex cardiostimulating effects of hydralazine.

  1977cited by this paper
• Discontinuation of maintenance digoxin therapy in general practice.

  1977cited by this paper
• Myocardial degeneration in mice treated with dibutyryl cyclic AMP and/or theophylline

  1976cited by this paper
• Cyclic adenosine monophosphate, ventricular fibrillation, and antiarrhythmic drugs.

  1976cited by this paper
• Diuretic-induced oedema.

  1975cited by this paper
• CANCER, ASTHMA, AND CYCLIC A.M.P.

  1975cited by this paper
• Intracellular calcium and myocardial contractility. V. Calcium uptake of sarcoplasmic reticulum fractions in hypertrophied and failing rabbit hearts.

  1974cited by this paper
• Biochemical “Defect’ in the Hypertrophied and Failing Heart: Deleterious or Compensatory?

  1973cited by this paper
• Digitalis intoxication. A prospective clinical study with serum level correlations.

  1971cited by this paper
• Some biochemical studies on subcellular systems isolated from fresh recipient human cardiac tissue obtained during transplantation.

  1971cited by this paper
• Digitalis intoxication.

  1971cited by this paper
• Maintenance Digoxin in Elderly Patients

  1970cited by this paper
• Rate of Calcium Binding and Uptake in Normal Animal and Failing Human Cardiac Muscle: MEMBRANE VESICLES (RELAXING SYSTEM) AND MITOCHONDRIA

  1969cited by this paper
• The hemodynamic effects of ouabain upon the diseased left ventricle.

  1968cited by this paper
• Toxicity--a frequent complication of digitalis therapy.

  1966cited by this paper
• STUDIES ON DIGITALIS. X. EFFECTS OF OUABAIN ON FOREARM VASCULAR RESISTANCE AND VENOUS TONE IN NORMAL SUBJECTS AND IN PATIENTS IN HEART FAILURE.

  1964cited by this paper
• Observations on Digitalis Intoxication—A Plea

  1964cited by this paper
• Hemodynamic Effects of Digoxin in Latent Cardiac Failure

  1962cited by this paper
• Observations on digitalis intoxication.

  1961cited by this paper

• Understanding Heart Failure: Evolution of Concepts and Treatments

  2024cites this paper
• A Novel Neuromodulation Approach to Improve LV Contractility in Heart Failure: A First-in-Human Proof-of-Concept Study.

  2020cites this paper
• Heart Plasticity in Response to Pressure- and Volume-Overload: A Review of Findings in Compensated and Decompensated Phenotypes

  2020cites this paper
• Deleterious cardiovascular effect of exosome in digitalis‐treated decompensated congestive heart failure

  2020cites this paper
• Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials

  2019cites this paper
• Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies

  2019cites this paper
• Beta blockers: effects Beyond Heart Rate Control

  2018cites this paper
• Cardiac contractility modulation improves left ventricular systolic function partially via miR-25 mediated SERCA2A expression in rabbit trans aortic constriction heart failure model.

  2018cites this paper
• Digoxin and Heart Failure: Are We Clear Yet?

  2017cites this paper
• Clinical Aspects of Sympathetic Activation and Withdrawal in Heart Failure

  2016cites this paper
• The expanding GRK interactome: Implications in cardiovascular disease and potential for therapeutic development.

  2016cites this paper
• Incremental prognostic value of echocardiographic strain and its association with mortality in cancer patients.

  2015cites this paper
• Chronic Inotropic Therapy in the Current Era: Old Wines With New Pairings.

  2015cites this paper
• Team-Based Care for Outpatients with Heart Failure.

  2015cites this paper
• G protein receptor kinase type 2: A novel target in cardiovascular drug development

  2014cites this paper
• Gene- and Cell-Based Therapy for Cardiovascular Disease

  2014cites this paper
• Adrenergic Nervous System in Heart Failure: Pathophysiology and Therapy

  2013influential citation
• GRK-2 inhibitor lek kandidat u terapiji srčane insuficijencije

  2013cites this paper
• GRK2 inhibition in heart failure: something old, something new.

  2012cites this paper
• Cardiac contractility modulation in the treatment of heart failure: initial results and unanswered questions

  2011cites this paper
• Two candidates at the heart of dysfunction: The ryanodine receptor and calcium/calmodulin protein kinase II as potential targets for therapeutic intervention-An in vivo perspective.

  2011cites this paper
• GRK2 and β-arrestins in cardiovascular disease: Something old, something new.

  2011cites this paper
• The acute inotropic effects of cardiac contractility modulation (CCM) are associated with action potential duration shortening and mediated by β1-adrenoceptor signalling

  2011cites this paper
• GRK2 as a novel gene therapy target in heart failure.

  2011cites this paper
• Optimisation of Digoxin Maintenance Dose in Toxicity

  2010cites this paper
• Biological actions and metabolism of currently used pharmacological agents for the treatment of congestive heart failure.

  2009cites this paper
• Medical management of advanced heart failure

  2008cites this paper
• Gene therapy in heart failure.

  2008cites this paper
• Designing heart performance by gene transfer.

  2008cites this paper
• Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapy.

  2007cites this paper
• Impact of phosphodiesterase 4D on cardiac β2 adrenergic receptor signaling

  2007cites this paper
• Chronic inotropic therapy in end-stage heart failure.

  2006cites this paper
• The Amiodarone Derivative KB130015 [2-Methyl-3-(3,5-diiodo-4-carboxymethoxybenzyl)benzofuran] Induces an Na+-Dependent Increase of [Ca2+] in Ventricular Myocytes

  2006cites this paper
• Cardiac contractility modulation by non‐excitatory currents: Studies in isolated cardiac muscle

  2006cites this paper
• Management of Acute Decompensated Heart Failure: Treatment, Controversy, and Future Directions

  2006cites this paper
• Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.

  2006cites this paper
• [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure].

  2005cites this paper
• Executive summary of the guidelines on the diagnosis and treatment of acute heart failure

  2005cites this paper
• The Amiodarone Derivative KB130015 [2-Methyl-3-(3,5-diiodo-4-carboxymethoxybenzyl)benzofuran] Induces an Na (cid:1) Dependent Increase of [Ca 2 (cid:1) ] in Ventricular Myocytes

  2005cites this paper
• Guidelines on the diagnosis and treatment of acute heart failure—full text The Task Force on Acute Heart Failure of the European Society of Cardiology

  2005cites this paper
• Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.

  2005cites this paper
• Something old, something new: changing views on the cellular mechanisms of heart failure.

  2005cites this paper
• Nonexcitatory electrical signals for enhancing ventricular contractility: rationale and initial investigations of an experimental treatment for heart failure.

  2005cites this paper
• Guidelines on the diagnosis and treatment of acute heart failure — full

  2005cites this paper
• The Amiodarone Derivative KB 130015 [ 2-Methyl-3-( 3 , 5-diiodo-4-carboxymethoxybenzyl ) benzofuran ] Induces an Na-Dependent Increase of [ Ca 2 ] in Ventricular Myocytes

  2005cites this paper
• Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca aguda. Versión resumida

  2005cites this paper
• [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure].

  2005cites this paper
• Wytyczne postępowania Europejskiego Towarzystwa Kardiologicznego (European Society of Cardiology - ESC) W porozumieniu z Europejskim Towarzystwem Intensywnej Terapii (European Society of Intensive Care Medicine - ESICM)

  2005cites this paper
• Long‐term effects of non‐excitatory cardiac contractility modulation electric signals on the progression of heart failure in dogs

  2004cites this paper
• Nonexcitatory stimulation as a novel treatment for heart failure: cause for excitement?

  2004cites this paper
• A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation

  2004cites this paper
• Intropic agents in the treatment of heart failure: Despair or hope?

  2004cites this paper
• Electric Currents Applied During the Refractory Period Can Modulate Cardiac Contractility In Vitro and In Vivo

  2004cites this paper
• Genetic and phenotypic targeting of β-adrenergic signaling in heart failure

  2004cites this paper
• Genetic manipulation of myocardial beta-adrenergic receptor activation and desensitization.

  2004cites this paper
• Electrical Modulation of Cardiac Contractility: Clinical Aspects in Congestive Heart Failure

  2004cites this paper
• βARK1 Inhibition Improves Survival in a Mouse Model of Heart Failure Induced by Myocardial Infarction

  2004cites this paper
• (cid:1) ARK1 Inhibition Improves Survival in a Mouse Model of Heart Failure Induced by Myocardial Infarction

  2004cites this paper
• Cardioprotective effects of exercise training on myofilament calcium activation in ovariectomized rats.

  2004cites this paper
• Altered cardiac calcium handling in diabetes

  2004cites this paper
• Cardiac contractility modulation with nonexcitatory electric signals improves left ventricular function in dogs with chronic heart failure.

  2003cites this paper
• The beta-adrenergic receptor kinase in heart failure.

  2003cites this paper
• Association of serum digoxin concentration and outcomes in patients with heart failure.

  2003influential citation
• Outcomes in Patients With Heart Failure Association of Serum Digoxin Concentration and

  2003influential citation
• The β-adrenergic receptor kinase in heart failure

  2003cites this paper
• Digoxin in heart failure and cardiac arrhythmias

  2003cites this paper
• Inotropic therapy is unsuccessful: wrong conceptual target or wrong therapeutic tools?

  2003cites this paper
• Targeting signaling pathways in heart failure by gene transfer

  2003cites this paper
• Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study).

  2002influential citation
• Gene transfer of β-adrenergic signaling components for heart failure

  2002cites this paper
• Signaling pathways that influence extracellular remodeling.

  2002cites this paper
• A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy.

  2002cites this paper
• Gene transfer of beta-adrenergic signaling components for heart failure.

  2002cites this paper
• Cardiac contractility modulation by electric currents applied during the refractory period.

  2002cites this paper
• Genetic manipulation of b-adrenergic signalling in heart failure

  2001cites this paper
• Genetic manipulation of beta-adrenergic signalling in heart failure.

  2001cites this paper
• Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family.

  2001cites this paper
• Gene Therapy Strategies to Augment Contractile Function in Heart Failure

  2001cites this paper
• Pathophysiology of chronic heart failure.

  2001cites this paper
• The case against outpatient parenteral inotropic therapy for advanced heart failure.

  2000cites this paper
• Update on digoxin therapy in congestive heart failure.

  2000cites this paper
• Catecholamines, Cardiac b-Adrenergic Receptors, and Heart Failure

  2000cites this paper
• The case against outpatient parenteral inotropic therapy for advanced heart failure

  2000cites this paper
• Catecholamines, cardiac beta-adrenergic receptors, and heart failure.

  2000cites this paper
• Current medical therapy for advanced heart failure.

  2000cites this paper
• Investigation on SCH00013, a Novel Cardiotonic Agent with Ca++ Sensitizing Action

  1999cites this paper
• Diagnostic and prognostic indicators in chronic heart failure.

  1999cites this paper
• Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial.

  1999cites this paper
• Current medical therapy for advanced heart failure.

  1998cites this paper
• To dig or not to dig.

  1998cites this paper
• Digoxin revisited.

  1998cites this paper
• Cardiac Sodium Channels as Targets for New Inotropic Agents

  1998cites this paper
• [Digoxin: continuous or discontinuous treatment?].

  1998cites this paper
• Definition und Therapieansatz

  1998cites this paper
• Stellenwert der PDE-III-Hemmstoffe in der Behandlung der Herzinsuffizienz

  1998cites this paper
• Chronic heart failure in the United States: a manifestation of coronary artery disease.

  1998cites this paper
• Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure.

  1998cites this paper
• Mini-review QJM Digoxin revisited

  1998cites this paper
• Crosstalk of the heart and periphery: skeletal and cardiac muscle as therapeutic targets in heart failure.

  1997cites this paper
• Growth hormone: a newcomer in cardiovascular medicine.

  1997cites this paper